Previous close | 44.40 |
Open | 45.78 |
Bid | 38.95 |
Ask | 41.70 |
Strike | 330.00 |
Expiry date | 2023-09-15 |
Day's range | 44.40 - 45.78 |
Contract range | N/A |
Volume | |
Open interest | 109 |
The FDA approves Eli Lilly's Jaypirca (pirtobrutinib) under an accelerated approval pathway as a treatment for mantle cell lymphoma (MCL).
AstraZeneca's (AZN) Evusheld is no longer authorized for use in the United States after laboratory data showed that it does not neutralize Omicron subvariants.
Biogen (BIIB) and Eisai jointly announce that EMA accepts lecanemab's marketing authorization application (MAA) for the treatment of patients with early-stage Alzheimer's disease, for review.